Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Limertinib and Sintilimab in EGFR-Mutant NSCLC
NCT07038460Phase 2Not yet recruiting
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Limertinib -> Sintilimab + Chemo with Limertinib -> Limertinib + Chemo (2 arms). Primary endpoint: Pathologic Complete Response Rate. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
limertinibsintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07038460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07038460.